Table 6.
Univariable Predictors of Non-Response to Antiviral Therapy.
| Parameter | Univariable OR | 95% CI | p Value | |
|---|---|---|---|---|
| Age | 1 | 0.96–1.03 | 0.8187 | |
| BMI | 1.15 | 1.05–1.25 | 0.0031 | |
| BMI | <25 | Ref. level | ||
| 25 or more | 12.83 | 1.68–97.88 | 0.0139 | |
| Genotype 3 | no | Ref. level | ||
| yes | 7.05 | 2.45–20.29 | 0.0003 | |
| Genotype 4 | no | Ref. level | ||
| yes | 2.32 | 0.29–18.25 | 0.4243 | |
| Any comorbidity | no | Ref. level | ||
| yes | 1.87 | 0.42–8.33 | 0.4139 | |
| Hypertension | no | Ref. level | ||
| yes | 0.46 | 0.13–1.66 | 0.2371 | |
| Diabetes | no | Ref. level | ||
| yes | 5.17 | 1.81–14.81 | 0.0022 | |
| Renal disease | no | Ref. level | ||
| yes | 1.69 | 0.38–7.64 | 0.4928 | |
| Autoimmune diseases | no | Ref. level | ||
| yes | NA (0 in cell) | |||
| Non-HCC tumors | no | Ref. level | ||
| yes | NA (0 in cell) | |||
| Other comorbidity | no | Ref. level | ||
| yes | 1.85 | 0.52–6.59 | 0.3446 | |
| Concomitant medications | no | Ref. level | ||
| yes | 2.27 | 0.64–8.09 | 0.2072 | |
| Liver fibrosis | F0 | Ref. level | ||
| F1 | NA (0 in cell) | |||
| F2 | NA (0 in cell) | |||
| F3 | NA (0 in cell) | |||
| F4 | NA (0 in cell) | |||
| Liver fibrosis, F4 | no | Ref. level | ||
| yes | 4.43 | 1.59–12.38 | 0.0045 | |
| Ascites | no | Ref. level | ||
| yes | 2.41 | 0.31–18.97 | 0.4043 | |
| Encephalopathy | no | Ref. level | ||
| yes | 6.62 | 0.79–55.29 | 0.0809 | |
| Documented esophageal varices |
no | Ref. level | ||
| yes | 4.89 | 1.63–14.62 | 0.0046 | |
| Moderate ascites at baseline |
no | Ref. level | ||
| yes | NA (0 in cell) | |||
| Tense ascites at baseline |
no | Ref. level | ||
| yes | NA (0 in cell) | |||
| Encephalopathy at baseline |
no | Ref. level | ||
| yes | NA (0 in cell) | |||
| HCC history | no | Ref. level | ||
| yes | NA (0 in cell) | |||
| OLTx history | no | Ref. level | ||
| yes | NA (0 in cell) | |||
| MELD | 14 or less | Ref. level | ||
| 15–18 | NA (0 in cell) | |||
| 19–20 | NA (0 in cell) | |||
| 21 or more | NA (0 in cell) | |||
| Child Pugh B or C | no | Ref. level | ||
| yes | 7.56 | 2.03–28.19 | 0.0026 | |
| HBV coinfection HBsAg plus |
no | Ref. level | ||
| yes | NA (0 in cell) | |||
| HIV coinfection | no | Ref. level | ||
| yes | NA (0 in cell) | |||
| Cryoglobulinemia | no | Ref. level | ||
| yes | 1.76 | 0.62–4.99 | 0.2866 | |
| History of previous therapy |
Treatment-naive | Ref. level | ||
| Nonresponder | 2.44 | 0.51–11.7 | 0.2645 | |
| Relapser | 5.01 | 1.47–17.05 | 0.0098 | |
| Discontinuation due to safety reason | 2.06 | 0.25–16.84 | 0.4998 | |
| History of previous therapy |
Treatment naive | Ref. level | ||
| Treatment experienced | 3.33 | 1.19–9.29 | 0.0216 | |
| Therapy | AS + DCV | Ref. level | ||
| LDV/SOF +/− RBV | 0.18 | 0.02–2.15 | 0.1778 | |
| OBV/PTV/r +/− DSV +/− RBV | 0.21 | 0.02–2.13 | 0.1867 | |
| GZR/EBR +/− RBV | 0.11 | 0.01–1.76 | 0.1176 | |
| SOF + SMV +/− RBV | NA (0 in cell) | |||
| SOF + DCV +/− RBV | NA (0 in cell) | |||
| SOF + RBV | 1.03 | 0.09–12.27 | 0.9799 | |
| GLE/PIB | 0.31 | 0.03–2.9 | 0.3025 | |
| SOF/VEL +/− RBV | 0.26 | 0.02–3.08 | 0.2886 | |
| ALT | 1 | 1–1.01 | 0.1092 | |
| ALT | <70 | Ref. level | ||
| 70 or more | 4.85 | 1.53–15.35 | 0.0072 | |
| Bilirubin | 1.12 | 0.88–1.43 | 0.3501 | |
| Bilirubin | <0.98 | Ref. level | ||
| 0.98 or more | 5.07 | 1.72–14.98 | 0.0033 | |
| Albumin | 0.31 | 0.12–0.85 | 0.0231 | |
| Creatinine | 0.98 | 0.39–2.42 | 0.9596 | |
| Hemoglobin | 1.14 | 0.82–1.59 | 0.4286 | |
| Platelets | 0.99 | 0.98–1 | 0.0045 | |
| PLT | <115 | Ref. level | ||
| 115 or more | 0.17 | 0.06–0.47 | 0.0007 | |
| HCV RNA | 0.99 | 0.91–1.08 | 0.8547 |
ALT: alanine transaminase; ASV: asunaprevir; BMI: body mass index; DCV: daclatasvir; DSV: dasabuvir; EBR: elbasvir; F: fibrosis; GLE: glecaprevir; GZR: grazoprevir; HBsAg: hepatitis B surface antigen; HBV: hepatitis B virus; HCC: hepatocellular carcinoma; HCV RNA: ribonucleic acid of hepatitis C virus; HIV: human immunodeficiency virus; LDV: ledipasvir, NA: not available; OBV: ombitasvir, OLTx,: orthotopic liver transplantation; RBV: ribavirin; Ref.: reference; SMV: simeprevir; SOF: sofosbuvir; PIB: pibrentasvir; PTV/r: paritaprevir; VEL: velpatasvir.